



Company Profile

Our Mission

To successfully market the world's first non-invasive system which accurately detects and alerts users of sleep-time hypoglycaemia.

Our Purpose

To help people with IDDM detect and prevent sleep-time hypoglycemic attacks.

Our Values

1. Exceed customer expectations
2. Scientific & Corporate Integrity
3. Excellence in partnerships
4. Creating shareholder value

Our Vivid Description

AIMEDICS technology is globally accessible to people with IDDM and is recognised as the method to reduce the risk of sleep-time hypoglycaemia.

Our Management Approach

AIMEDICS is an Australian Innovative Medical Device Company. Our success is built on the quality of our people and management practices.

Our Corporate Governance

The actions of our people are guided by our mission, values and quality management system.

Our History

AIMEDICS was established in 2001 based on the work and patents of two inventors from the University of Technology Sydney (UTS). Since then, it has been funded through a series of investments and government grants; BIF, NSW government, JDRF (through UTS) and the Australian federal government.


The original technology concepts have been upgraded and developed into the clinically tested HypoMon® product. This first output of the technology platform is targeted as a nocturnal hypoglycaemia monitor and alarm for use by young Type 1 diabetes patients. Initial product sales are scheduled to occur in Australia and Europe during 2011.

Our Flagship Product

The HypoMon® provides safer sleep for people with Type 1 diabetes aged between 10 and 25 years. It is non-invasive and accurately identifies and alerts the user and carer to hypoglycaemia. Key product benefits include accurate detection and alert of sleep-time hypo, non-invasive and comfortable, simple and easy to use, and affordable.

Our Contact Details

Phone: 02 9209 4514
Email: info@hypomon.com
Website: www.hypomon.com



Monitor + Alarm + Treat = 😊

HypoMon®
A safer night's sleep.